RxDoctor Payments Data

Olukayode Oladeji, MD

Interventional Cardiology · East Brunswick, NJNPI 1376579086

Payments from drug & device makers

$434in general payments, 2019–2025

Across 19 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$214
  • Novo Nordisk$82
  • AbbVie$56
  • Merck$22
  • Novartis$20
  • Alkermes, Inc.$16
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$41395%
  • Education$225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott5$214
Novo Nordisk5$82
AbbVie(2 entities)4$56
Merck1$22
Novartis1$20
Alkermes, Inc.1$16
Pfizer1$13
Johnson & Johnson1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$434 in reported general payments places this provider in the 5th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$365,966
Medicare patients
592
Services billed
3,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$352,389
OzempicSemaglutide55$102,538
XareltoRivaroxaban86$98,723
JardianceEmpagliflozin92$94,082
EntrestoSacubitril/Valsartan48$58,080
JanuviaSitagliptin Phosphate50$46,124
TrulicityDulaglutide22$40,275
BrilintaTicagrelor29$27,121
MultaqDronedarone Hcl13$26,638
FarxigaDapagliflozin Propanediol18$19,393
NexletolBempedoic Acid21$15,766
Breo ElliptaFluticasone/Vilanterol26$13,912
Isosorbide Dinitrate44$9,593
Nebivolol Hcl129$7,204
Metoprolol Succinate481$6,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$352,389318 claims
Novo NordiskOzempic$82$102,53855 claims
Johnson & JohnsonXarelto$11$98,72386 claims
NovartisEntresto$20$58,08048 claims
MerckJanuvia$22$46,12450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →